Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $714.00 | Total: $3,570.00 |
| 1 | 10 | $604.80 | Total: $6,048.00 |
| 1 | 25 | $512.40 | Total: $12,810.01 |
| 1 | 50 | $436.80 | Total: $21,840.00 |
| 1 | 100 | $378.00 | Total: $37,800.02 |
Overview
ARRY-403 is a novel glucokinase activator that reduces fasting and postprandial blood glucose in patients with type 2 diabetes.
Chemical Properties
| Molecular Formula | C20H18N6O3S2 |
| Molecular Weight | 454.52 |
| CAS Numbers | 1138669-65-4 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Cc1ncccc1Oc1cc(Sc2ccccn2)cnc1Nc1nc(ns1)[C@H](O)CO |
Storage and Handling
0C Short Term, -20C Long Term
References
Katz L, et al. AMG 151 [ARRY-403], a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes Obes Metab. 2016 Feb;18[2] 191-5.